Submit your Abstract
Monday, 15 January 2024, 23:59 CET
Submission deadline
Elevate your professional profile as a recognised expert in your specialised area of knowledge. Prepare and submit your abstract now.
ESOC 2024 provides you with the ideal platform to showcase your regular abstract or late breaking abstract onsite in Basel. Authors interested in submitting an abstract for ESOC 2024 have the option to choose from a diverse range of topics.
Prepare your abstract submission
Defintions of Topics
Clinical Trial Definition
A research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include placebo or other control) to evaluate the effects of those interventions (such as novel drugs, specific devices, behavioural therapy etc.) on health-related biomedical or behavioural outcomes).
When submitting a clinical trial, please always indicate the trial registration number (e.g., clinicaltrials.gov NO).
Ongoing Trials Topic
Is only for proposed posters that will describe the design and/or progress of an ongoing trial – i.e., trials that will not have closed in time to present results at ESOC 2024.
Studies Excluding Clinical Trials
Is for all studies which do NOT qualify as clinical trial as defined above.
Placeholder Abstract
- If you anticipate submitting your final results as a late-breaking contribution (see definition below), it is obligatory to select the “PLACEHOLDER Late Breaking Trials” in the regular abstract submission.
- This will assist the conference committee in reserving a suitable slot on the programme and you can update your abstract with results during the late breaking submission in March.
How to proceed:
- Go to the online abstracts’ submission services now (deadline 15 January 2024)
- Prepare your abstract and select “PLACEHOLDER Late Breaking Trials”. (Your abstract can describe a trial/large study and the analyses that will soon be available).
- Follow the submission steps and provide preliminary information such as Title, Background and Aims etc
- In March 2024 you will be contacted by our services to inform you that the Late Breaking Abstract submission system is open (only for the LB) – You will then be available to update the content of your abstract.
- Once updated, press on the Submit Button (do not forget this action or it won’t be considered in the final selection)
Late Breaking Science:
- Results of clinical trials or high impact large studies that will only be complete after this deadline (but in time to release results at the conference) can be submitted to the late breaking science section. It is important to mention why the submitted science is of high impact.
Review the submission guidelines
Guidelines for the preparation of abstracts
Please carefully read the below Guidelines for the preparation of your abstract.
- Online submission only – Abstracts sent by fax or email will not be accepted.
- Authors should indicate their presentation type preference:
- Poster presentation only
- Oral or poster presentation
Note: “Poster presentation only” implies that your abstract will be considered for poster presentation only.
- One person may serve as presenting author on up to 5 abstracts.
- The Scientific Programme Committee reserves the right to decide on the final allocation and presentation method.
- All abstracts should be submitted and presented in clear UK English with accurate grammar and spelling of a quality suitable for publication. If you need help, arrange for the review of your abstract by a colleague who is a native English speaker, by a university specific publications office (or other similar facility) or by a copy editor, prior to submission.
- You may enter up to 10 authors in the authors list including the presenter.
If you have more than 10 authors, you can use the “On behalf of” field to enter the name of an investigating team/study group. - The presenting author of an accepted abstract must register and attend the congress to ensure the publication of abstracts.
- Submission of an abstract acknowledges your acceptance for the abstract to be published in the official conference publications.
- The presenting author is required to ensure that all co-authors are aware of the content of the abstract and agree to its submission, before submitting the abstract.
- Abstracts that have been previously presented at another international meeting cannot be considered for a plenary session.
- Abstract title – must be in UPPER CASE and limited to 25 words. Please submit symbols as words.
- Abstract text – limited to 250 words including acknowledgements. Note that word count is affected when tables are included. Tables (3 max) may be added at the end of the template (word file).
- Abstracts should clearly state:
Background and aims
Methods
Results
Conclusions - Use only standard abbreviations. Place special or unusual abbreviations in parentheses after the full word the first time it appears.
- Use generic names of drugs. The presentation must be balanced and contain no commercial promotional content.
- Images – The maximum file size of each image is 500 KB. The maximum pixel size of the graph/image is 600(w) x 800(h) pixel. You may upload images in JPG, GIF or PNG format. Images (3 max) may be added at the end of the template (word file).
- Submissions may not contain patient names, hospital ID numbers or other identifying information.
- Disclosure of Conflicts of Interest: Please disclose any conflict of interests the authors might have and indicate in the custom queries during the submission process.
- Important:
As the grading and selection process is blind, the title and body text must not contain identifying features, i.e. information such as:- Names (authors or others)
- Names of the institutes (hospitals, medical schools, clinics…)
- Cities
- Make sure to state your correct e-mail address. After having submitted your abstract, you will receive a confirmation by e-mail with the following information:
• reference number of your abstract (for correspondence and questions that might arise)
• title of your submitted abstract
If you do not receive a confirmation by e-mail, please contact ESOC.abstracts@congrex.com - Should you wish to make corrections to an abstract already submitted or if you wish to submit other abstracts later, you may use your personal log-in. This will shorten the submission procedure.
Corrections to abstracts can only be made up to the deadline of 15 January 2024, 23:59h CET.
Notification
Each abstract will be reviewed and rated by at least 4 external blinded experts and final selection will be made by the Scientific Programme Committee. Notification of acceptance or rejection of submitted abstracts will be sent to the corresponding authors via email by mid-March 2024. Full instructions concerning preparation and presentation will be included and will be made available on the conference website.
Publication
ESOC 2024 has an embargo policy on all abstracts submitted to the conference. The embargo will be lifted on 15 May 2024. All accepted abstracts will be published in the peer-reviewed journal.
Questions?
If you have questions regarding abstracts technical questions or need assistance, contact the abstract team at ESOC.Abstracts@congrex.com including/referring to the name of the congress.
Abstract hotline: +41 61 686 77 22 (Monday – Friday during business hours)
Travel Grants and Award Information
Travel Grants:
- WHO IS ELIGIBLE?
Abstract presenting authors, who are residents of a country classified with low-income and lower-middle-income economies, according to the World Bank Country Classification. - GRANT RULES
- Travel Grant receivers are chosen among presenting authors whose abstract is among best scoring (only of those eligible for this grant).
- Presenting authors must have submitted their abstract to the Conference via the website.
- Awardees will need to provide banking details for transfer of the travel grant. The transfer will only be made after the Conference.
- Awardees’ names and institutions will be published on the Conference website.
- HOW TO APPLY
- Via the abstract submission
- Applicants must submit a copy of their passport. The required documents should be submitted during the abstract submission in the indicated fields.
- Notification of acceptance or rejection will be sent to the corresponding authors via email by latest end of March 2024.
Young Investigator Award:
- WHO IS ELIGIBLE?
Abstract presenting authors, who are early career researchers, aged maximum 35 years at the opening date of the Conference. - AWARD RULES
Awardees will be chosen among presenting authors whose abstract is among best scoring (only of those eligible for this award).
Presenting authors must have submitted their abstract to the Conference via the website.
Awardees will need to provide banking details for transfer of the award. The transfer will only be made after the Conference.
Awardees’ names and institutions will be published on the Conference website. - HOW TO APPLY
Via the abstract submission
Applicants must submit a copy of their passport, a brief CV and a signed statement from the senior author in the group that indicates in reasonable detail the young investigator’s contribution, where there are co-authors or study group collaborators. The required documents should be submitted during the abstract submission in the indicated fields. - Notification of acceptance or rejection will be sent to the corresponding authors via email by mid/latest end of March 2024.
YSPR – Study Design Workshop
This is a focused workshop for early career investigators.
The aim of this workshop is to support young stroke researchers in promoting their proposed or ongoing research project to the ESOC audience. They will be given the opportunity to present their work and receive feedback from an expert mentor. The goal of this feedback is to allow young researchers to optimise their study design.
As in previous years, young investigators (≤35 years) will be invited to submit an abstract for the workshop describing their research project, preferably a project still under development or interim results from an ongoing project. Abstracts can be submitted to ESOC as a special category ( “4.30 YSPR – Study Design Workshop”).
The successful applicants will give an oral presentation, followed by constructive assessment of the study’s design and advice on its future development by a senior, internationally renowned invited investigator. In addition to providing expert guidance on the development of the study, the workshop will be an opportunity for the young researchers to promote their work to the wider community and establish collaborations.
The presenters of the two top scoring abstracts will receive a place at the ESO Summer School or the ESO Edinburgh Stroke Winter School in 2024. All presenters will be interviewed by other Young Stroke Physicians and Researchers and the interviews will be featured on the ESO blog.
Consult the category list
| 1,00 |
Clinical Trials |
| 1,01 | ACUTE MANAGEMENT – NEITHER THROMBOLYSIS NOR THROMBECTOMY |
| 1,02 | ACUTE MANAGEMENT – THROMBOLYSIS OR THROMBECTOMY |
| 1,03 | PREVENTION |
| 1,04 | REHABILITATION & RECOVERY |
| 2,00 |
Placeholder Late Breaking Trials (Results available at the conference) |
| 2,01 | PLACEHOLDER – NEITHER THROMBOLYSIS NOR THROMBECTOMY |
| 2,02 | PLACEHOLDER – THROMBOLYSIS OR THROMBECTOMY |
| 2,03 | PLACEHOLDER – PREVENTION |
| 2,04 | PLACEHOLDER – REHABILITATION & RECOVERY |
| 3,00 |
ONGOING TRIALS (Poster only, results are NOT available at the conference) |
| 3,01 | ONGOING TRIALS |
| 4,00 |
STUDIES – EXCLUDING TRIALS |
| 4,01 | HYPERACUTE MANAGEMENT – EXCLUDING CLINICAL TRIAL RESULTS |
| 4,02 | THROMBOLYSIS – EXCLUDING CLINICAL TRIAL RESULTS |
| 4,03 | NEUROINTERVENTION – EXCLUDING CLINICAL TRIAL RESULTS |
| 4,04 | SECONDARY PREVENTION – EXCLUDING CLINICAL TRIAL RESULTS |
| 4,05 | REHABILITATION – EXCLUDING CLINICAL TRIAL RESULTS |
| 4,06 | EPIDEMIOLOGY & RISK FACTORS |
| 4,07 | IMAGING – HYPERACUTE |
| 4,08 | IMAGING – NON ACUTE |
| 4,09 | DIAGNOSIS/INVESTIGATION OF STROKE ETIOLOGY |
| 4,10 | PROGNOSIS AND OUTCOME AFTER STROKE |
| 4,11 | STROKE COMPLICATIONS |
| 4,12 | CEREBROVASCULAR MANIFESTATIONS OF INFECTIONS |
| 4,13 | ATHEROSCLEROSIS |
| 4,14 | RARE CAUSES including dissection |
| 4,15 | STROKE IN THE YOUNG (INCLUDING PAEDIATRIC STROKE) |
| 4,16 | CARDIOEMBOLISM & HEART-BRAIN INTERACTIONS |
| 4,17 | INTRACEREBRAL HAEMORRHAGE |
| 4,18 | SAH, ANEURYSMS AND VASCULAR MALFORMATIONS |
| 4,19 | COGNITION AND VASCULAR COGNITIVE IMPAIRMENT |
| 4,02 | SMALL VESSEL DISEASE |
| 4,21 | SEX, GENDER AND STROKE |
| 4,22 | PATHOPHYSIOLOGY OF STROKE / TRANSLATIONAL MEDICINE |
| 4,23 | GENETICS, ‘OMICS AND BIOMARKERS |
| 4,24 | CLINICAL PRACTICE, MANAGEMENT AND CARE |
| 4,25 | PRE-HOSPITAL SERVICE ORGANISATION |
| 4,26 | SERVICE ORGANISATION incl. quality improvement |
| 4,27 | BRAIN REORGANISATION AND RECOVERY |
| 4,28 | TECHNOLOGY INNOVATIONS: ROBOTS, VIRTUAL REALITY, ARTIFICIAL INTELLIGENCE AND MORE |
| 4,29 | CASE REPORTS |
| 4,30 | YSPR – Study Design Workshop |
You might also be interested in
